Trial intelligence / Profile preview

RECARDO: Docetaxel plus carboplatin versus docetaxel in hormone refractory prostate cancer after prior docetaxel response

2007-004335-39Phase 2Active

Sponsor: Amsterdam University Medical Center
Start: Mar 2009
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised trial in prostate cancer (PCa) comparing Docetaxel monotherapy with Docetaxel plus carboplatin (2 arms). Primary endpoints: Progression-free survival, Toxicity profile and 1 more. Started Mar 2009; status: active.

Drugs

docetaxelcarboplatin

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on 2007-004335-39.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-004335-39.